Preview: CROs & CDMOs

CDMOs and CROs are under great pressure to integrate new trial designs and drug formats – including  ATMPs, ADCs, condensate blockers, RNA drugs and formulations as well as automated preclinical testing procedures – into their service portfolio, while at the same time facing a global shortage of qualified personnel. In addition to classic antibody and conjugate drugs and various RNA drugs and vaccines, and increasingly to produce cell and gene therapeutics, the first in vivo CRISPR treatments or synthetic peptide hormone combinations are entering the market.